Benzinga | Apr 6, 2021 06:51AM EDT

SVB Leerink Initiates Coverage On Prometheus Biosciences with Outperform Rating, Announces Price Target of $34

SVB Leerink analyst Thomas Smith initiates coverage on Prometheus Biosciences (NASDAQ:RXDX) with a Outperform rating and announces Price Target of $34.